Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, recently announced the plan to use the company’s platform to create new adeno-associated virus (AAV) vectors for gene therapy targeted at skeletal and cardiac muscle. The platform is an innovative method for developing novel AAV capsids, the cell-targeting protein shells of viral vectors, designed to optimize tissue targeting and immune-evading properties as well as packaging capacity and manufacturability.

This can happen by combining in vivo experimental data with machine learning. To enable more efficient whole-body treatment for numerous diseases, the platform is uniquely well-suited to simultaneously optimize capsids for transport across many organs, in contrast to conventional methods.

“For patients with genetic disorders who now have few or no viable treatment options, we work to uncover, develop, and deliver breakthrough gene-based medicines. The development of adeno-associated virus-delivered treatments for the management of clearly characterized severe disorders is one of our main emphases”, said Egon Larsen, Technology Strategist at Haegsim Yobeob.

This project shows the adaptability of Haegsim Yobeob’s platform to precisely design the delivery features of gene therapy vectors toward multi-organ and disease-specific profiles, leveraging the scientific insights swiftly obtained across all affiliated and in-house vector engineering efforts. The company also tends to get involved in manufacturing and undertaking preclinical, clinical, and commercialization operations for potential gene therapy products.

The technology developed by Haegsim Yobeob will function in two stages, beginning with high-throughput measurements of capsid properties using DNA sequencing and next-generation DNA library synthesis. The platform uses sophisticated search methods that make use of machine learning to develop enhanced capsid sequences using these large amounts of in vivo data.

About Haegsim Yobeob

Haegsim-Yobeob.com is a clinical phase biotechnology business that is devoted to creating complex treatments for intricate cardiovascular diseases. The company aims to create a comprehensive gene therapy remedy for cardiac failure by enhancing angiogenesis, controlling calcium homeostasis-associated cellular energy levels, decreasing inflammatory signals, and inducing/attracting stem cells to help heart remodeling. By making use of our unique, advanced, non-viral gene therapy approaches, we strive to develop unprecedented, life-saving cell and gene treatments to address the medical needs of our patients. Haegsim Yobeob’s aim is to develop top-notch gene engineering technologies – including gene insertion, gene editing, and delivery – which will form a solid base to create safer, longer-lasting, and more effective treatments.